表皮生长因子受体突变与非小细胞肺癌脑转移的相关性研究进展

doi:10.3969/j.issn.1003-9198.2025.03.020

摘要/Abstract

摘要： 肺癌位居全国老年人群致死恶性肿瘤的第1位。脑转移是造成肺癌病人较差预后的重要原因。非小细胞肺癌(NSCLC)是肺癌中的常见类型。此综述旨在深入探讨NSCLC病人中表皮生长因子受体(EGFR)突变与脑转移间的相关性,及存在脑转移的EGFR突变NSCLC病人的治疗方案,着重探讨了EGFR酪氨酸激酶抑制剂(EGFR-TKI)的靶向治疗新进展。

关键词: 非小细胞肺癌, 脑转移, 表皮生长因子受体突变

Abstract: Lung cancer ranks as the leading cause of cancer-related mortality among the elderly population. Brain metastases represent a significant factor contributing to the poor prognosis of the patients with lung cancer. Non-small cell lung cancer(NSCLC) is a common subtype of lung cancer.This review aims to comprehensively examine the correlation between epidermal growth factor receptor(EGFR) mutations and the occurrence of brain metastases in NSCLC patients, as well as the treatment strategies for those with EGFR-mutant NSCLC who present with brain metastases, especially the targeted therapy provided by the latest epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs).

Key words: non-small cell lung cancer, brain metastases, epidermal growth factor receptor

中图分类号:

R 734.2

方亭文, 曾璐琳, 卢凯华. 表皮生长因子受体突变与非小细胞肺癌脑转移的相关性研究进展[J]. 实用老年医学, 2025, 39(3): 303-307.

FANG Tingwen, ZENG Lulin, LU Kaihua. Relationship between EGFR mutation and brain metastases in non-small cell lung cancer[J]. Practical Geriatrics, 2025, 39(3): 303-307.

参考文献

[1] CHANGA Y, SKIRBEKKV F, TYROVOLAS S, et al. Measuring population ageing: an analysis of the global burden of disease study 2017[J]. Lancet Public Health, 2019, 4(3): e159-e167.
[2] 陈万青, 郑荣寿, 张思维, 等. 2012年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2016, 25(1): 1-8.
[3] GU X, ZHENG R, XIA C, 等. 中国预期寿命与癌症发病率和死亡率的相互影响: 基于人群的聚类分析[J]. 癌症, 2019, 38(1): 23-38.
[4] HERBSTR S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
[5] DA CUNHA SANTOS G, SHEPHERDF A, TSAOM S. EGFR mutations and lung cancer[J]. Annu Rev Pathol, 2011, 6: 49-69.
[6] MCGRANAHAN T, NAGPAL S. A neuro-oncologist's perspective on management of brain metastases in patients with EGFR mutant non-small cell lung cancer[J]. Curr Treat Options Oncol, 2017, 18(4): 22.
[7] SCHOENMAEKERS J J A O, DINGEMANSA C, HENDRIKSL E L. Brain imaging in early stage non-small cell lung cancer: still a controversial topic?[J]. J Thorac Dis, 2018, 10(Suppl 18): S2168-S2171.
[8] HUANGR S P, HARRIES L, DECKER B, et al. Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases[J]. Oncologist, 2022, 27(10): 839-848.
[9] JIMENO A, HIDALGO M. Pharmacogenomics of epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors[J]. Biochim Biophys Acta, 2006, 1766(2): 217-229.
[10] MOSESSON Y, YARDEN Y. Oncogenic growth factor receptors: implications for signal transduction therapy[J]. Semin Cancer Biol, 2004, 14(4): 262-270.
[11] HUANGS F, LIUH P, LIL H, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan[J]. Clin Cancer Res, 2004, 10(24): 8195-8203.
[12] WUW S, CHENY M, TSAIC M, et al. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer[J]. J Chin Med Assoc, 2013, 76(12): 682-685.
[13] KONG C, YIN X, ZOU J, et al. The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung[J]. BMC Cancer, 2024, 24(1): 454.
[14] ZHAO W, ZHOU W, RONG L, et al. Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer[J]. Front Oncol, 2022, 12: 912505.
[15] WANG G, XU J, QI Y, et al. Distribution of brain metastasis from lung cancer[J]. Cancer Manag Res, 2019, 11: 9331-9338.
[16] TAKANO K, KINOSHITA M, TAKAGAKI M, et al. Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor[J]. Neuro Oncol, 2016, 18(5): 716-724.
[17] SEKINE A, KATO T, HAGIWARA E, et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features[J]. Lung Cancer, 2012, 77(1): 64-69.
[18] HEON S, YEAPB Y, BRITTG J, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib[J]. Clin Cancer Res, 2010, 16(23): 5873-5882.
[19] HOCHMAIR M. Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and/or leptomeningeal disease[J]. Target Oncol, 2018, 13(3): 269-285.
[20] NISHINO M, SOEJIMA K, MITSUDOMI T. Brain metastases in oncogene-driven non-small cell lung cancer[J]. Transl Lung Cancer Res, 2019, 8(Suppl 3): S298-S307.
[21] MURRAYK J, SCOTT C, GREENBERGH M, et al. A randomized phase Ⅲ study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group(RTOG) 9104[J]. Int J Radiat Oncol Biol Phys, 1997, 39(3): 571-574.
[22] BYEON S, HAMJ S, SUNJ M, et al. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis[J]. Med Oncol, 2016, 33(8): 97.
[23] BOWDEN G, KANO H, CAPAROSA E, et al. Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer[J]. J Neurosurg, 2015, 122(4): 766-772.
[24] CHANGE L, WEFELJ S, HESSK R, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial[J]. Lancet Oncol, 2009, 10(11): 1037-1044.
[25] MULVENNA P, NANKIVELL M, BARTON R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy(QUARTZ): results from a phase 3, non-inferiority, randomised trial[J]. Lancet, 2016, 388(10055): 2004-2014.
[26] ANDREWSD W, SCOTTC B, SPERDUTOP W, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial[J]. Lancet, 2004, 363(9422): 1665-1672.
[27] PATIL C G, PRICOLA K, MANUEL SARMIENTO J, et al. Whole brain radiation therapy(WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases[J]. Cochrane Database Syst Rev, 2017, 9(9): CD006121.
[28] PALMERJ D, KLAMERB G, BALLMANK V, et al. Association of long-term outcomes with stereotactic radiosurgery vs whole-brain radiotherapy for resected brain metastasis: asecondary analysis of the N107C/CEC.3(alliance for clinical trials in oncology/Canadian cancer trials group) randomized clinical trial[J]. JAMA Oncol, 2022, 8(12): 1809-1815.
[29] AOYAMA H, SHIRATO H, TAGO M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial[J]. JAMA, 2006, 295(21): 2483-2491.
[30] GONDI V, PUGHS L, TOMEW A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases(RTOG 0933): a phase II multi-institutional trial[J]. J Clin Oncol, 2014, 32(34): 3810-3816.
[31] RAPPS R, DOUG CASE L, PEIFFER A, et al. Donepezil for irradiated brain tumor survivors: a phase Ⅲ randomized placebo-controlled clinical trial[J]. J Clin Oncol, 2015, 33(15): 1653-1659.
[32] BEARZ A, GARASSINO I, TISEO M, et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer[J]. Lung Cancer, 2010, 68(2): 264-268.
[33] ORTUZAR W, HANNA N, PENNELLA E, et al. Brain metastases as the primary site of relapse in two randomized phase Ⅲ pemetrexed trials in advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2012, 13(1): 24-30.
[34] OUS I, ZHUV W. CNS metastasis in ROS1+ NSCLC: an urgent call to action, to understand, and to overcome[J]. Lung Cancer, 2019, 130: 201-207.
[35] BURIOLLA S, PELIZZARI G, CORVAJA C, et al. Immunotherapy in NSCLC patients with brain metastases[J]. Int J Mol Sci, 2022, 23(13): 7068.
[36] TAYLORM H, SCHMIDTE V, DUTCUS C, et al. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors[J]. Future Oncol, 2021, 17(6): 637-648.
[37] POPAT S, AHNM J, EKMAN S, et al. Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies[J]. Target Oncol, 2023, 18(1): 9-24.
[38] PARK K, TANE H, O'BYRNE K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer(LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. Lancet Oncol, 2016, 17(5): 577-589.
[39] GROMMES C, OXNARDG R, KRISM G, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer[J]. Neuro Oncol, 2011, 13(12): 1364-1369.
[40] CROSSD A E, ASHTONS E, GHIORGHIU S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J]. Cancer Discov, 2014, 4(9): 1046-1061.
[41] HOCHMAIR M, HOLZER S, BURGHUBERO C. Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases[J]. Anticancer Drugs, 2016, 27(9): 914-915.
[42] MOKT S, WUY L, AHNM J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med, 2017, 376(7): 629-640.
[43] TOGASHI Y, MASAGO K, MASUDA S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer[J]. Cancer Chemother Pharmacol, 2012, 70(3): 399-405.
[44] CHENG Y, LIANGS K, WEIY F, et al. Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients[J]. Anal Biochem, 2023, 669: 115115.
[45] KATAYAMA T, SHIMIZU J, SUDA K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib[J]. J Thorac Oncol, 2009, 4(11): 1415-1419.